Dialysis world news

Efficacy of EVE/BEV, IFN/BEV Similar in Metastatic Renal Cell Carcinoma - Cancer Therapy Advisor PDF Print
April 14, 2015 Efficacy of EVE/BEV, IFN/BEV Similar in Metastatic Renal Cell Carcinoma - Cancer Therapy Advisor
Efficacy of first-line everolimus/bevacizumab and interferon alfa-2a/bevacizumab appears similar in metastatic RCC.

The efficacy of first-line everolimus/bevacizumab and interferon alfa-2a/bevacizumab appears similar in patients with metastatic renal cell carcinoma, a recent study published online early in the journal Annals of Oncology has shown.

For the open-label, phase II RECORD-2 trial, researchers sought to compare the safety and efficacy of everolimus plus bevacizumab with interferon plus bevacizumab as first-line therapy for patients with metastatic renal cell carcinoma.

Researchers enrolled 365 untreated patients and randomly assigned them 1:1 to bevacizumab 10mg/kg every 2 weeks with either everolimus 10mg/day or interferon 9MIU three times weekly, if tolerated.

Results showed that median progression-free survival was 9.3 months in the everolimus arm and 10.0 months in the interferon arm (P = 0.485). Researchers found that median overall survival was 27.1 months in both treatment arms.

RELATED: Cabozantinib Granted Fast-Track Designation for Renal Cell Carcinoma

In regard to safety, 23.4% from the everolimus arm and 26.9% from the interferon arm discontinued treatment due to adverse events.

The most common grade 3-4 adverse events in the everolimus/bevacizumab group were proteinuria, stomatitis, and anemia versus fatigue, asthenia, and proteinuria in the interferon/bevacizumab group.


  1. Ravaud A, Barrios CH, Alekseev B, et al. RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alfa-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2015. [Epub ahead of print]. doi: 10.1093/annonc/mdv170.


Acetaminophen Blunts Pleasure as Well as Pain - Renal and Urology News PDF Print
April 14, 2015 Acetaminophen Blunts Pleasure as Well as Pain - Renal and Urology News
Researchers have found that the popular over-the-counter pain reliever acetaminophen may not only relieve a person's pain, but may also blunt positive emotions.

Researchers have found that the popular over-the-counter pain reliever acetaminophen may not only relieve a person's pain, but may also blunt positive emotions. Results of the study were published online in the journal Psychological Science.

In the study,  participants were asked to evaluate both negative and positive images from the International Affective Picture System. Photographs ranged from extremely unpleasant (crying, malnourished children), to neutral (cow in a field) to very pleasant (young children playing with cats). Participants were then asked to rate the images on a scale of -5 (extremely negative) to +5 (extremely positive); photos were viewed again and participants were asked to rate their emotional reaction from a scale of 0 (little or no emotion) to 10 (extreme amount of emotion).

Compared to those who took placebo, individuals in the acetaminophen group evaluated unpleasant images less negatively and pleasant ones less positively. The acetaminophen group also rated positive and negative images as less emotionally arousing, with an average level of emotion of 5.85 when they saw extreme photos. Those in the placebo group rated their level of emotion relatively high (average score 6.76) when they saw emotionally jarring photos. 

The results of this study were further reproduced in a second study, however when participants were asked to report on the extent of color saturation in the images, judgments of color content were similar regardless of drug condition.

The authors conclude that acetaminophen may have a general blunting effect on a person's evaluative and emotional processing. This study also offers support to a new theory that says common factors may influence how sensitive a person is to positive and negative life events. It is not known whether other pain relievers such as ibuprofen and aspirin have the same effect.

For more information visit OSU.edu.


Repeat Prostate Biopsies Find Significant Cancers - Renal and Urology News PDF Print
April 14, 2015 Repeat Prostate Biopsies Find Significant Cancers - Renal and Urology News
Researchers found an increased likelihood of prostate cancer with fourth repeat biopsy and in patients older than 70.

(HealthDay News) -- Among a group of men with an initial negative prostate biopsy, clinically significant cancer is still found in subsequent repeat sampling rounds, according to a study published in the April issue of The Journal of Urology.

Nitya E. Abraham, M.D., from the New York University School of Medicine in New York City, and colleagues collected data on 1,837 men who underwent prostate biopsy (Jan. 1, 1995, to Jan. 1, 2010). The authors sought to determine characteristics of repeat biopsy (indication for biopsy, the number of repeat biopsies performed, the number of cores obtained, and total prostate-specific antigen before biopsy), as well as features of prostate cancer diagnosed on repeat biopsy (including Gleason score, number of positive cores, percent of tumor and treatment choice).

The researchers found that 1,213 men had negative initial biopsies, but that 798 repeat biopsies were performed in 255 men. Gleason score was ?6 in 33 of 63 men diagnosed with prostate cancer, 7 in 22, and 8 to 9 in 8 men. Using Epstein criteria, the rate of clinically insignificant cancer diagnosis decreased substantially by the third and fourth repeat biopsies. An increased likelihood of prostate cancer diagnosis was seen in men ?70 years with repeat biopsies, biopsies including more than 20 cores, and the fourth repeat biopsy.

"Given the continued likelihood of cancer detection even by the fifth biopsy, early consideration of saturation or image guided biopsy may be warranted in the repeat biopsy population," the authors write.

One author disclosed financial ties to the pharmaceutical and medical device industries.


  1. Abraham, NE, et al. The Journal of Urology; doi: http://dx.doi.org/10.1016/j.juro.2014.10.084.


Dialysis Modalities Show Similar Outcomes in AKI - Renal and Urology News PDF Print
April 14, 2015 Dialysis Modalities Show Similar Outcomes in AKI - Renal and Urology News
Research revealed no significant difference in the risk of death between continuous renal replacement therapy and extended daily dialysis.

Data from randomized controlled trials show that extended daily dialysis and continuous renal replacement therapy for acute kidney injury (AKI) are associated with similar outcomes, according to the authors of a recently published meta-analysis.

Extended daily dialysis (EDD) was associated with decreased mortality compared with continuous renal replacement therapy (CRRT) in observational studies, but such studies are potentially subject to allocation or selection bias, researchers reported online ahead of print in the American Journal of Kidney Diseases.

A team led by Rinaldo Bellomo, MD, PhD, Austin Health, Heidelberg, Victoria, Australia, analyzed data from 17 studies: 7 randomized controlled trials (RCTs) and 10 observational studies. The 17 studies included 634 patients undergoing EDD and 574 undergoing CRRT.

RCTs revealed no significant difference in the risk of death between EDD and CRRT, but observational studies show that EDD was associated with a 16% decreased relative risk of mortality compared with CRRT.

Both the RCTs and observation studies demonstrated no significant difference between the modalities with respect to kidney recovery, fluid removal, length of stay in the intensive care unit, and laboratory findings (serum urea, serum creatinine, and serum phosphate).

The investigators stated that, to their knowledge, their study is the first to systematically evaluate the effect of EDD versus CRRT on patients with AKI.


NxStage Kidney Care Brings Dialysis Options to Pittsburgh Area - MarketWatch PDF Print

                  LAWRENCE, Mass., April 14, 2015 /PRNewswire/ -- NxStage® Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. 

                                    NXTM, -0.16%

                                         today announced the opening of its Monroeville, Pennsylvania dialysis center, offering local patients several flexible therapy options. Conveniently located in Allegheny County, the NxStage Kidney Care Pittsburgh team is comprised of highly trained medical staff committed to providing dialysis patients with high quality, personalized and compassionate care.

                  The new facility offers customized therapy options using the NxStage System One™, including home hemodialysis (HHD), home nocturnal hemodialysis, flexible in-center hemodialysis, and short-term respite care. Additionally, the center offers peritoneal dialysis (PD) therapy. All NxStage Kidney Care centers feature comprehensive home dialysis training tailored to the unique needs of each patient.

                  "We make home dialysis training and education about treatment options a focus here. Our goal is to work with patients to help them optimize their lives outside of dialysis," said Dr. Subramoniam Jayakumar, Medical Director at NxStage Kidney Care Pittsburgh. "Our approach to patient care focuses on each patient's individual needs, and together we develop a therapy plan that is safe, effective, and flexible."

                  Like all NxStage Kidney Care facilities, the center is furnished with modern, comfortable amenities, offering a quiet and relaxed environment. A renal social worker provides education and guidance throughout the kidney transplant process, and a dietitian works with patients to craft personalized nutritional plans.

                  NxStage Kidney Care Pittsburgh invites local patients and their families to an educational session on Chronic Kidney Disease (CKD) and treatment options, including those offered at the center. Patients interested in attending the event can call the center at (412) 224-5757 for details or visit www.nxstagekidneycare.com/locations/pittsburgh.

                  NxStage Kidney Care Pittsburgh is located at 3623 William Penn Highway, Monroeville, PA 15146. For more information about NxStage Kidney Care's home and flexible in-center dialysis options please visit www.nxstagekidneycare.com.

        About NxStage Kidney Care 
        NxStage Kidney Care, Inc., a subsidiary of NxStage Medical, Inc. 

                                    NXTM, -0.16%

                                         is innovating a dialysis care model that is intended to support and encourage patient centered care and provide enhanced access to the life-changing benefits of home therapy as well as flexible in-center options. By leveraging NxStage's home leadership and the innovative technology of its System One, NxStage Kidney Care is committed to helping patients take control of their dialysis and to allowing physicians the flexibility to prescribe what is truly best for their patients. For more information, please visit www.nxstagekidneycare.com or call (866) 694-2707.

        About NxStage MedicalNxStage Medical, Inc. 

                                    NXTM, -0.16%

                                         is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the Company's website at www.nxstage.com.

        Forward-Looking Statements  This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Annual Report on Form 10-K for the year ended December 31, 2014. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

        Media contact:    
Kristen K. Sheppard, Esq.
This e-mail address is being protected from spambots. You need JavaScript enabled to view it  
Tel: (978) 332-5923 Logo- http://photos.prnewswire.com/prnh/20141008/150974   To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-kidney-care-brings-dialysis-options-to-pittsburgh-area-300065141.html SOURCE NxStage Kidney Care, Inc. Copyright (C) 2015 PR Newswire. All rights reserved


<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 5 of 2474
Share |
Copyright © 2015 Global Dialysis. All Rights Reserved.